24/7 Clients Support
| Brand Name | DASALIEVA 50mg |
| Composition | Dasatinib 50 mg |
| Manufacture By | Allieva Pharma Private Limited |
| Form | Tablet |
| Packing | Btl (60 Tab) |
| Country Of Origin | India |
| Description | Dasatinib is a potent tyrosine kinase inhibitor used in the treatment of leukemia. It blocks multiple kinases including BCR-ABL, SRC family kinases, and others involved in cancer cell growth. It is especially effective in patients with resistance or intolerance to other TKIs like imatinib. |
| Uses | Dasatinib 50 mg is used to treat: Chronic Myeloid Leukemia (CML) Chronic phase Accelerated phase Blast crisis CML resistant or intolerant to prior therapy Acute Lymphoblastic Leukemia (ALL) Philadelphia chromosome–positive (Ph+ ALL) Used alone or in combination with chemotherapy Other Uses (off-label / clinician-monitored) Ph+ leukemias with specific TK mutations Patients needing rapid reduction of leukocyte count |
| Side Effects | Common Side Effects Fluid retention (swelling, pleural effusion) Headache Fatigue Nausea, vomiting Diarrhea Skin rash Body aches / muscle pain Serious Side Effects (require immediate medical care) Pleural effusion / fluid around lungs Pulmonary arterial hypertension (PAH) Low blood counts (anemia, neutropenia, thrombocytopenia) Bleeding complications QT prolongation (heart rhythm issue) |
| Dosage | For Chronic Phase CML 100 mg once daily For Accelerated Phase, Myeloid or Lymphoid Blast Phase CML 140 mg once daily For Ph+ Acute Lymphoblastic Leukemia 140 mg once daily Dose Adjustments Dose may change based on: Blood count monitoring Side effects Response to therapy Interaction with other medicines |